These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18403540)

  • 1. Donors agree financial arrangement to stimulate vaccine development.
    Jack A
    BMJ; 2008 Apr; 336(7648):797. PubMed ID: 18403540
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic perspectives on the advance market commitment for pneumococcal vaccines.
    Snyder CM; Begor W; Berndt ER
    Health Aff (Millwood); 2011 Aug; 30(8):1508-17. PubMed ID: 21821567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dispute over pneumococcal vaccine initiative.
    Usher AD
    Lancet; 2009 Dec; 374(9705):1879-80. PubMed ID: 19998524
    [No Abstract]   [Full Text] [Related]  

  • 6. Developing countries roll out pneumococcal vaccine thanks to novel funding scheme.
    Kmietowicz Z
    BMJ; 2010 Dec; 341():c7230. PubMed ID: 21159770
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccines-all things considered. Part II. 2-3 December 2004, San Francisco, CA, USA.
    Rosenthal KS
    IDrugs; 2005 Feb; 8(2):110-1. PubMed ID: 15696409
    [No Abstract]   [Full Text] [Related]  

  • 8. Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers.
    Plahte J
    Vaccine; 2012 Mar; 30(14):2462-6. PubMed ID: 22300720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversial funding mechanism to fight pneumonia.
    Braine T
    Bull World Health Organ; 2008 May; 86(5):325-6. PubMed ID: 18545730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological equipment financing options and strategies: an automated pharmacy dispensing system example.
    Tucker W
    Health Care Innov; 1996; 6(5):25-8. PubMed ID: 10163586
    [No Abstract]   [Full Text] [Related]  

  • 11. Are good intentions putting the vaccination ecosystem at risk?
    Watson M; Faron de Goër E
    Hum Vaccin Immunother; 2016 Sep; 12(9):2469-74. PubMed ID: 27269046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GAVI's Advance Market Commitment.
    Schwalbe N; El-Ziq I
    Lancet; 2010 Feb; 375(9715):638-9. PubMed ID: 20171398
    [No Abstract]   [Full Text] [Related]  

  • 13. Addressing the vaccine financing conundrum.
    Hinman AR
    Health Aff (Millwood); 2005; 24(3):701-4. PubMed ID: 15886163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eurofile. Private-public drive to cut delays in drug development.
    Mundell I
    Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
    [No Abstract]   [Full Text] [Related]  

  • 16. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary care physician perspectives on reimbursement for childhood immunizations.
    Freed GL; Cowan AE; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1319-24. PubMed ID: 19047252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines: worth paying for the value returned.
    Grabenstein JD
    Ann Pharmacother; 2002 Sep; 36(9):1471-2. PubMed ID: 12229878
    [No Abstract]   [Full Text] [Related]  

  • 19. How vaccines are developed.
    Douglas RG
    Curr Clin Top Infect Dis; 1994; 14():192-204. PubMed ID: 8086115
    [No Abstract]   [Full Text] [Related]  

  • 20. Financing vaccines in the 21st century: recommendations from the National Vaccine Advisory Committee.
    Hinman AR;
    Am J Prev Med; 2005 Jul; 29(1):71-5. PubMed ID: 15958255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.